- Interpretable dimensionality reduction of single cell transcriptome data with deep generative models.
- The RNA-binding protein YBX1 regulates epidermal progenitors at a posttranscriptional level.
- Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
- Identification of cancer-associated missense mutations in hace1 that impair cell growth control and Rac1 ubiquitylation.
June 2, 2016
Building on the world’s largest breast cancer study, BC Cancer Agency scientists map the relationship between cancer mutations and clinical outcomes in 2,433 women. Dr. Samuel Aparicio co-led a study with Dr. Carlos Caldas from Cancer Research UK and these teams have shown that what lies beneath the surface is critical as no two breast […]
May 16, 2016
Roth A, et al. Clonal genotype and population structure inference from single-cell tumor sequencing. Nature Methods. 2016 May 16. doi: 10.1038/nmeth.3867. [Epub ahead of print] Our Nature Methods paper details a new statistical approach for analysing single cell genomics data. The manuscript describes a novel statistical model coupled with a mean field variational inference method […]
May 16, 2016
McPherson A, Roth A, Laks E, Masud T, Bashashati A, Zhang AW, Ha G, Biele J, Yap D, Wan A, Prentice L, Khattra J, Mullaly SC, Kalloger S, Karnezis A, Shumansky K, Siu C, Rosner J, Chan HL, Ho J, Melnyk N, Senz J, Yang W, Moore R, Mungall A, Marra MA, Bouchard-Cote A, Gilks […]
February 17, 2015
NSERC Brockhouse Prize For CycloMed99 17 February 2015 For their outstanding teamwork in realizing a solution for safe and reliable isotope production for hospitals in Canada, interdisciplinary research team CycloMed99 will be receiving a prestigious national award at a ceremony in Ottawa today. The Honourable David Johnston, Governor General of Canada, will present the NSERC Brockhouse Canada […]
Posted in Benard Lab, Media, News And Events | Tagged with BC Cancer Agency, BCCA, BCCRC, Benard, Brockhouse Prize, Cancer Research, Cyclotron, Francois Benard, Media, Medical Isotopes, NSERC, Radiology, Research, TRIUMF, UBC
January 24, 2011
New federal investments in BC Cancer Agency and TRIUMF will enable augmenting local supply of key medical isotope Vancouver—The Government of Canada today announced a $6 million investment to develop an alternative medical-isotope production technology proposed by TRIUMF and the BC Cancer Agency (BCCA). The team will leverage existing capabilities at TRIUMF and BCCA to […]
BC Cancer Agency and Pfizer Oncology scientists identify the P-cadherin protein as a prognostic biomarker in breast cancer
October 28, 2010
Scientists from the BC Cancer Agency and Pfizer Oncology have published the first results of their three-year research collaboration. The paper, published in the journal Modern Pathology, analyzed the expression of the P-cadherin protein in breast cancer. P-cadherin is involved in controlling the development and function of the normal mammary gland, but may also play […]
November 28, 2009
The world is facing a shortage of the key medical isotope Technetium-99m (Tc-99m). More than 80% of the estimated 1.5 million nuclear medicine procedures performed annually in Canada use radiopharmaceuticals based on this isotope, which is currently produced using nuclear reactors. Together with TRIUMF and other partners, the BC Cancer Agency (BCCA) has received a […]